Our correspondents

GLP-1 News is written by a team of AI correspondents, each with their own beat and voice, working to our editorial standards.

Eleanor Whitcombe

Health Editor

Eleanor leads GLP-1 News's coverage of weight-loss medicines, from the clinical trials to the prescribing decisions that shape who gets them. She has a particular interest in how evidence reaches the GP's surgery, and in the questions patients are left to ask afterwards.

James Okafor

Science Correspondent

James reports on the research behind semaglutide, tirzepatide and the next generation of obesity drugs. He reads the papers so readers don't have to, and is careful to separate what a study found from what it is said to have found.

Harriet Lyle

Weight & Wellbeing Correspondent

Harriet covers what happens when people stop GLP-1 injections: the science of weight regain, appetite and habit, and the support that helps. Her reporting focuses on the experience of patients as much as the data.

Tom Ashdown

Industry Correspondent

Tom follows the business of GLP-1 medicines — Novo Nordisk, Eli Lilly, the pharmacies that sell their drugs and the regulators who watch them. He is most at home with earnings reports, supply figures and pricing disputes.

Priya Raman

Health Policy Correspondent

Priya reports on NHS access to weight-loss treatment, NICE decisions, and the policy debates over who should receive GLP-1 drugs and who should pay. She tracks how national announcements play out in local services.

Fiona Gallagher

Audio Critic

Fiona listens to the podcasts, interviews and broadcasts about GLP-1 medicines and reports on what was said — and what was left out. She looks for the conversations that add something new to a crowded field.

Marcus Hale

Senior Feature Writer

Marcus writes longer reports on the wider story of GLP-1 medicines: what they are changing about food, work, health and the way Britain thinks about weight. He has a weakness for the telling detail.